FibroBiologics to Present at the DealFlow Discovery Conference

Rhea-AI Summary

FibroBiologics (Nasdaq: FBLG) announced that Founder and CEO Pete O’Heeron will present at the DealFlow Discovery Conference in Atlantic City on January 28-29, 2026. The company presentation is scheduled for 11:30 a.m. ET on January 29, 2026. FibroBiologics is a clinical-stage biotechnology company focused on therapeutics using fibroblasts and fibroblast-derived materials and holds 270+ patents issued and pending. Management will be available for one-on-one investor meetings during the event and provided contact details for further information.

News Market Reaction – FBLG

-3.70%

1 alert

-3.70% Session close to close

$22.82M Market Cap

0.0x Rel. Volume

In the Jan 20 session, FBLG declined 3.70%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights FibroBiologics’ continued outreach to the investment community, adding ...

Analysis

This announcement highlights FibroBiologics’ continued outreach to the investment community, adding another investor-focused presentation to a recent stream of clinical and financing updates. With the stock trading well below its $2.12 52-week high and under the $0.60 200-day MA, prior offerings and proxy proposals around capital structure remain important context. Investors may watch for future trial initiations, data readouts, and any additional financing or listing-related actions alongside these conference appearances.

Key Figures

Patent portfolio: 270+ patents issued and pending Conference dates: January 28–29, 2026 Presentation time: 11:30 a.m. ET +1 more

4 metrics

Patent portfolio 270+ patents issued and pending FibroBiologics IP portfolio noted in conference announcement

Conference dates January 28–29, 2026 DealFlow Discovery Conference timing

Presentation time 11:30 a.m. ET Scheduled company presentation on Thursday, January 29

52-week range $0.2201–$2.12 Pre-news 52-week low and high for FBLG

Historical Context

5 past events · Latest: Jan 07 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 07	Shareholder update	Positive	+32.3%	Detailed 2025 progress, new lab, trials, financings and debt payoff.
Jan 06	Conference presentation	Neutral	+6.8%	Announced CEO presentation at BFC Global healthcare investment conference.
Jan 05	Preclinical data	Positive	+1.5%	Reported positive FSdC preclinical results in degenerative disc disease models.
Dec 31	IND filing	Positive	-7.0%	Filed Phase 1/2 IND with FDA for CYPS317 in psoriasis.
Dec 16	Equity offering	Negative	-8.4%	Closed $1.7M registered direct offering with associated warrants.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has often aligned with price moves: positive clinical and corporate updates tended to see gains, while dilutive offerings saw declines. One notable divergence occurred when a positive IND filing was followed by a negative price reaction.

Recent Company History

Over the last several weeks, FibroBiologics reported multiple financing transactions and important clinical and corporate milestones. On Dec 16, 2025, a registered direct offering led to a -8.44% move. A Dec 31, 2025 IND filing for CYPS317 in psoriasis saw a -7.03% reaction despite being a clinical advancement. In early January 2026, positive preclinical FSdC data and a shareholder letter outlining new facilities, trials, and financings supported gains up to 32.27%. Conference presentation announcements have previously coincided with moderate upside.

Key Terms

clinical-stage

1 terms

clinical-stage medical

"a clinical-stage biotechnology company with 270+ patents issued and pending"

Clinical-stage describes a drug, therapy, or company whose product is being tested in human trials but has not yet received regulatory approval. For investors, it signals that the project has moved beyond lab work into real-world testing—meaning higher potential reward if trials succeed but also clear risks from trial setbacks, costs, and regulatory delay; think of it like a prototype car on public road tests that could either prove its value or reveal problems that stop it from reaching production.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOUSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the DealFlow Discovery Conference taking place January 28-29, 2026, at the Borgata in Atlantic City, New Jersey.

FibroBiologics will deliver a company presentation at 11:30 a.m. ET on Thursday, January 29 and will be available for one-on-one investor meetings throughout the event.

For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

General Inquiries:
info@fibrobiologics.com

Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

FAQ

When will FibroBiologics (FBLG) present at the DealFlow Discovery Conference?

FibroBiologics will present on January 29, 2026 at 11:30 a.m. ET.

Who from FibroBiologics will present at the January 2026 DealFlow Discovery Conference?

Founder and CEO Pete O’Heeron will deliver the company presentation.

Where is the DealFlow Discovery Conference where FBLG will present?

The conference takes place at the Borgata in Atlantic City, New Jersey on January 28-29, 2026.

How can investors schedule one-on-one meetings with FibroBiologics at the conference?

Investors can request meetings during the event and contact FibroBiologics via info@fibrobiologics.com or visit the company website.

What is FibroBiologics' business focus mentioned for the January 2026 presentation?

The company is a clinical-stage biotech focused on therapeutics and potential cures using fibroblasts and fibroblast-derived materials, with 270+ patents issued and pending.